Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetracosactide depot - Slan Medicinal Holdings

Drug Profile

Tetracosactide depot - Slan Medicinal Holdings

Alternative Names: Cosyntropin depot - Slan Medicinal Holdings; Long acting cosyntropin - Slan Medicinal Holdings; Synthetic ACTH Depot - Slan Medicinal Holdings

Latest Information Update: 28 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer Assertio Therapeutics; Slan Medicinal Holdings
  • Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Adrenal insufficiency
  • No development reported Infantile spasms

Most Recent Events

  • 28 Oct 2021 No recent reports of development identified for clinical-Phase-Unknown development in Infantile spasms in USA (Parenteral)
  • 24 Oct 2019 Update: KDM, HE
  • 21 Oct 2019 West Therapeutic Development (Slan Medicinal Holdings) receives complete response letter from the FDA for tetracosactide depot in Adrenal insufficiency (Diagnosis)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top